Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Molecular Probes Licenses Fluorescence Technology to LightUp

By HospiMedica staff writers
Posted on 24 Apr 2003
New DNA typing assays using fluorescence-based technology licensed from Molecular Probes (Eugene, OR, USA) are being launched by LightUp Technologies AB (Huddinge, Sweden). More...


These new assays, called LightUp Probes, can be used to identify and quantify the presence of bacteria, viruses, and other pathogens by detecting and analyzing DNA. Molecular Probes will supply advanced fluorescent stains for the assays that increase sensitivity in detecting DNA and other nucleic acids. The LightUp Probes are short peptide nucleic acid conjugates that increase in fluorescence when hybridized to target sequences. The technology is useful for identifying and quantifying targets in an extremely rapid, one-step homogenous hybridization assay. It can be used on its own or in combination with polymerase chain reaction (PCR).

"The combination of our innovative DNA typing technology and Molecular Probes' proprietary fluorescent stains is truly synergistic,” said Ulrica Sehlstedt, Ph.D., CEO of LightUp Technologies. "When enhanced with Molecular Probes' fluorescent stains, our LightUp Probes make DNA assays, including those using real-time PCR, even more sensitive, enabling their use in a wide variety of applications.”




Related Links:
Molecular Probes
LightUp Technologies

New
Gold Member
Aspiration System
VACUSAFE
New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Repetitive Pipette
VWR® Stepper Pro
New
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.